Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Short-term Investments (2016 - 2022)

Iradimed has reported Short-term Investments over the past 10 years, most recently at $500090.0 for Q1 2022.

  • Quarterly Short-term Investments fell 73.72% to $500090.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $500090.0 through Mar 2022, down 73.72% year-over-year, with the annual reading at $501855.0 for FY2021, 73.72% down from the prior year.
  • Short-term Investments was $500090.0 for Q1 2022 at Iradimed, roughly flat from $501855.0 in the prior quarter.
  • Over five years, Short-term Investments peaked at $8.2 million in Q2 2018 and troughed at $500090.0 in Q1 2022.
  • The 5-year median for Short-term Investments is $2.8 million (2019), against an average of $3.6 million.
  • Year-over-year, Short-term Investments increased 16.34% in 2018 and then plummeted 73.72% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $6.3 million in 2018, then crashed by 56.4% to $2.8 million in 2019, then crashed by 31.03% to $1.9 million in 2020, then tumbled by 73.72% to $501855.0 in 2021, then fell by 0.35% to $500090.0 in 2022.
  • Per Business Quant, the three most recent readings for IRMD's Short-term Investments are $500090.0 (Q1 2022), $501855.0 (Q4 2021), and $945066.0 (Q3 2021).